Production of canine hepatocyte-like cells from stem cell sources
Item Status
Embargo End Date
Date
Authors
Abstract
The cost of drug development is high with many drugs failing during toxicity testing.
This is a particular problem in veterinary medicine where the pharmaceutical market
size is so small that it may not be economically viable to develop drugs. The liver
and specifically hepatocytes have a crucial role in drug metabolism via oxidation by
cytochrome enzymes (CYP), conjugation and excretion into the biliary system. This
drug metabolism is unpredictable between species as each has unique CYP profiles.
Furthermore there is breed variation of CYP profiles within the canine species. The
ability to produce an in vitro source of canine hepatocytes to model drug metabolism
in this species and in different breeds would greatly reduce the expense of candidate
drug testing. If an unlimited supply could be produced in vitro this would reduce the
number of animals required in pre-clinical testing. The aim of this thesis was to
produce an in vitro supply of canine hepatocyte-like cells from stem cell sources,
namely hepatic progenitor cells (HPC), mesenchymal stem cells (MSC) or induced
pluripotent stem cells (iPSC). Cultures of canine primary hepatocytes were produced
to use as a gold standard, but also to develop and refine tests of hepatocyte
characterisation and function. A panel of primers was developed for use in real time
polymerase chain reaction (PCR) as well as optimising tests for low density
lipoprotein (LDL) and indocyanine green uptake, albumin production, periodic acid-
Schiff staining for glycogen and CYP activity using a luciferase-based system. As
primary hepatocytes rapidly lost their defining characteristics and function in vitro,
methods of maintaining function using CYP inducers and culture substrates were
assessed.
Isodensity centrifugation and magnetic-activated cell sorting was employed to isolate
HPCs. Selection of cells from the non-parenchymal cell fraction with stem cell
marker Prominin 1 demonstrated that these were keratin 7 positive, a HPC marker.
Cells morphologically consistent with HPC appeared and expanded in culture after 2
weeks. On passaging, these cells failed to continue expanding, despite plating onto
collagen, laminin, SNL feeder cells or using Kubota’s medium (known to allow rapid
expansion of rodent and human HPCs). Canine adipose (Ad-MSC) and bone marrow-derived mesenchymal stromal cells
(BM-MSC) were isolated post mortem. These were characterised as CD45, 105 and
STRO-1 positive, CD11b, 19 and 45 negative cells which could be differentiated into
adipocytes, chondrocytes and osteocytes based on staining characteristics and
relative gene expression. Protocols published for other species were used to
differentiate both Ad-MSC and BM-MSC towards a hepatocyte phenotype.
Although a dramatic change in morphology and a reduction in vimentin gene
expression were noted, suggesting a loss of mesenchymal phenotype, these protocols
did not induce a hepatocyte phenotype. Pre-treatment with 5-Aza-2′-deoxycytidine
to cause DNA demethylation and valproic acid to inhibit histone deacetylation also
failed to allow transdifferentiation.
A polycistronic vector containing Oct-4, c-Myc, Sox2 and Klf4 was successfully
transfected into canine epidermal keratinocyte progenitor cells which became
alkaline phosphatase positive and assumed a morphology consistent with iPSC. After
colony selection and expansion, PCR evidence of plasmid presence was lost, colony
morphology changed, and alkaline phosphatase activity reduced, consistent with
vector expression factor and pluripotency loss.
Canine iPSCs produced by lentiviral method were then differentiated towards
hepatocyte phenotype using a published protocol for mouse and human iPSC. These
cells were then assessed for hepatocyte characteristics using the developed reagents
and primers. These cells demonstrated increased gene expression and morphology
consistent with differentiation towards a hepatocyte-like phenotype.
This thesis demonstrates successful culture of canine primary hepatocytes and
validation of tests of hepatocyte phenotype. This provides a basis for optimising
primary hepatocyte function in vitro and assessment of the success of differentiation
protocols on stem cell sources. Canine mesenchymal stromal cells do not appear to
transdifferentiate towards a hepatocyte-like phenotype using published protocols for
other species. Canine iPSC are a promising candidate for an in-vitro source of
hepatocyte-like cells.
This item appears in the following Collection(s)

